Director, Drug Safety
Join Nurix’s pharmacovigilance team to help ensure patient safety across our clinical pipeline of targeted protein degradation therapies. As Director, Drug Safety, you’ll lead aggregate safety analysis, benefit–risk assessments, and safety strategy for assigned programs — shaping how we evaluate risk and bring new medicines safely to patients. It’s a chance to influence critical safety decisions at the intersection of clinical medicine, data, and drug development.
The Opportunity
Medical Safety Leadership
- Serve as the medical safety lead for assigned products, providing clinical and pharmacovigilance expertise to safety strategy and activities
- Lead aggregate safety data analysis for signal detection, signal evaluation, and risk characterization
- Conduct medical review and interpretation of safety data, contributing to benefit–risk assessments
- Monitor emerging safety signals and proactively address potential safety risks through appropriate internal and external communication
Regulatory and Safety Documentation
- Oversee medical review of Individual Case Safety Reports (ICSRs)
- Author and review regulatory safety documents, including Development Safety Update Reports (DSURs) and safety sections of INDs and regulatory briefing books
- Contribute to safety responses to regulatory authorities and participate in regulatory interactions
- Provide clinical leadership during inspections and audits related to safety and risk management
Clinical Development Support
- Provide clinical input into safety aspects of clinical trial protocols, informed consent forms, and investigator brochures
- Collaborate with clinical development, regulatory affairs, medical affairs, and other stakeholders to ensure a consistent global safety strategy
Governance and Cross-Functional Collaboration
- Serve on safety governance committees, supporting strategic decision-making for risk mitigation and benefit–risk evaluation
What You’ll Bring
- Advanced clinical or scientific degree, such as MD, DO, PharmD, or equivalent relevant training and experience
- Clinical experience preferred
- 5–10 years of experience in pharmacovigilance/drug safety within the pharmaceutical or biotechnology industry
- Experience supporting early clinical development and small biotechnology companies
- Demonstrated expertise in aggregate safety analysis and benefit–risk evaluation
- Strong knowledge of global pharmacovigilance regulations and guidance (ICH, FDA, EMA, MHRA)
- Experience interacting with global health authorities on safety matters
- Familiarity with signal detection and safety surveillance tools and databases
- Strong communication, collaboration, and cross-functional leadership skills
- Ability to interpret complex clinical and safety data and translate insights into regulatory and business strategy
- Ability to work effectively and collaboratively in a fast-paced, growing organization across functional boundaries
Salary Range: Non-MD $247,300 - $280,400 | MD $295,000 - $317,100
The posted range applies to roles based in the San Francisco Bay Area and reflects local market conditions. Where an offer lands within that range depends on the candidate’s relevant experience, technical expertise, and how their background aligns with the role’s requirements.
Location: Onsite – Brisbane, CA
Fit with Nurix Culture and Values
- Strong team orientation; highly collaborative
- Solutions and results-oriented focus
- Hands-on approach; resourceful and open to diverse points of view
About Nurix Therapeutics
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.
